- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Resistance of mitochondrial p53 to dominant inhibition ; volume:7 ; number:1 ; day:12 ; month:6 ; year:2008 ; pages:1-17 ; date:12.2008
Molecular cancer ; 7, Heft 1 (12.6.2008), 1-17, 12.2008
- Urheber
-
Heyne, Kristina
Schmitt, Katrin
Mueller, Daniel
Armbruester, Vivienne
Mestres, Pedro
Roemer, Klaus
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-4598-7-54
- URN
-
urn:nbn:de:101:1-2021082807473902819329
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Heyne, Kristina
- Schmitt, Katrin
- Mueller, Daniel
- Armbruester, Vivienne
- Mestres, Pedro
- Roemer, Klaus
- SpringerLink (Online service)
Ähnliche Objekte (12)
Caveolin-1 promotes glioma progression and maintains its mitochondrial inhibition resistance
Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamics
Mitochondrial oxidative phosphorylation in autosomal dominant optic atrophy
Metabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPR‐Cas9 screen
FGF1 induces resistance to chemotherapy in ovarian granulosa tumor cells through regulation of p53 mitochondrial localization
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Bcl2 inhibition of mitochondrial DNA repair
Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition
Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy
Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers
Caveolin-1 promotes glioma progression and maintains its mitochondrial inhibition resistance
Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamics
Mitochondrial oxidative phosphorylation in autosomal dominant optic atrophy
Metabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPR‐Cas9 screen
FGF1 induces resistance to chemotherapy in ovarian granulosa tumor cells through regulation of p53 mitochondrial localization
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Bcl2 inhibition of mitochondrial DNA repair
Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition
Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy
Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers
Caveolin-1 promotes glioma progression and maintains its mitochondrial inhibition resistance
Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamics
Mitochondrial oxidative phosphorylation in autosomal dominant optic atrophy
Metabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPR‐Cas9 screen
FGF1 induces resistance to chemotherapy in ovarian granulosa tumor cells through regulation of p53 mitochondrial localization
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Bcl2 inhibition of mitochondrial DNA repair
Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition
Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy